Algernon has retained CRO Clinical Development Solutions (“CDS”), to support all aspects of the investigational brochure, study protocol and Pre-IND and IND application with the U.S. FDA as well as the CTA with Health Canada. CDS will provide high-level oversight and management of all clinical trials.
The Company has also retained Novotech to conduct a feasibility study for Algernon to conduct all or part of its DMT stroke clinical research program in Australia. The Company has currently engaged Novotech for its Phase 2 clinical study for idiopathic pulmonary fibrosis and chronic cough as well as COVID-19. Australia is a favoured country for clinical research because of its government supported 43.5% refundable tax credit program.
Algernon is also exploring conducting its DMT clinical research program in other countries as well.